Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Prima BioMed Ltd (NASDAQ:PBMD)

0.8299
Delayed Data
As of Dec 02
 +0.0098 / +1.19%
Today’s Change
0.72
Today|||52-Week Range
1.54
-27.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$57.0M

Company Description

Prima BioMed Ltd. is a biotechnology company, which engages in developing oncology therapies in the field of immunotherapy. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Contact Information

Prima BioMed Ltd.
95 Pitt Street
Sydney New South Wales (nsw) 2000
P:(129) 276-1224
Investor Relations:

Employees

Shareholders

Other institutional0.18%
Mutual fund holders0.01%
Individual stakeholders--

Top Executives

Marc VoigtChief Executive Officer & Executive Director
Frédéric TriebelChief Scientific & Medical Officer
Larisa ChisholmManager-Business Development
Stuart RobertsInvestor Relations Contact
Deanne MillerCo-Secretary & General Counsel